PMN (ProMIS Neurosciences) ROCE %: -116.10% (As of Mar. 2026)


PMN ProMIS Neurosciences Inc PMN
30 GF Score
Price $13.39
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences ROCE %?

ProMIS Neurosciences PMN +22.42% 30 ROCE % is -116.10% as of Mar. 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ProMIS Neurosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -116.10%.

ProMIS Neurosciences  (NAS:PMN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ProMIS Neurosciences ROCE % Related Terms

ProMIS Neurosciences ROCE % Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences ROCE % Chart

ProMIS Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -117.02 -205.19 -544.28 27.25 -513.73

ProMIS Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.06 -872.53 -1,037.17 -1,065.14 -116.10
PMN
30GF Score
ProMIS Neurosciences Inc PMN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences ROCE % Calculation

ProMIS Neurosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-39.719/( ( (18.911 - 2.218) + (9.182 - 10.412) )/ 2 )
=-39.719/( (16.693+-1.23)/ 2 )
=-39.719/7.7315
=-513.73 %

ProMIS Neurosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-34.58/( ( (9.182 - 10.412) + (67.412 - 6.615) )/ 2 )
=-34.58/( ( -1.23 + 60.797 )/ 2 )
=-34.58/29.7835
=-116.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -116.10% mean?
ProMIS Neurosciences (PMN) has a ROCE % of -116.10% as of Mar. 2026.
Is ProMIS Neurosciences' ROCE % too high?
ProMIS Neurosciences' current ROCE % is -116.10%. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' ROCE % compare to BMEA and ANIX?
ProMIS Neurosciences' ROCE % of -116.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. ProMIS Neurosciences's current ROCE % is -116.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current ROCE % of -116.10%. The current ROCE % is -116.10%. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current ROCE % is -116.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score

Get the complete analysis for PMN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.39
Price